194 related articles for article (PubMed ID: 36053908)
21. Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer.
Kawaguchi H; Terai Y; Tanabe A; Sasaki H; Takai M; Fujiwara S; Ashihara K; Tanaka Y; Tanaka T; Tsunetoh S; Kanemura M; Ohmichi M
J Ovarian Res; 2014 Apr; 7():38. PubMed ID: 24713296
[TBL] [Abstract][Full Text] [Related]
22. Drug-Loaded Plant-Virus Based Nanoparticles for Cancer Drug Delivery.
Bruckman MA; Czapar AE; Steinmetz NF
Methods Mol Biol; 2018; 1776():425-436. PubMed ID: 29869258
[TBL] [Abstract][Full Text] [Related]
23. Immunogenicity and protective efficacy of candidate universal influenza A nanovaccines produced in plants by Tobacco mosaic virus-based vectors.
Petukhova NV; Gasanova TV; Stepanova LA; Rusova OA; Potapchuk MV; Korotkov AV; Skurat EV; Tsybalova LM; Kiselev OI; Ivanov PA; Atabekov JG
Curr Pharm Des; 2013; 19(31):5587-600. PubMed ID: 23394564
[TBL] [Abstract][Full Text] [Related]
24. Biodistribution, pharmacokinetics, and blood compatibility of native and PEGylated tobacco mosaic virus nano-rods and -spheres in mice.
Bruckman MA; Randolph LN; VanMeter A; Hern S; Shoffstall AJ; Taurog RE; Steinmetz NF
Virology; 2014 Jan; 449():163-73. PubMed ID: 24418549
[TBL] [Abstract][Full Text] [Related]
25. Tobacco mosaic virus as a new carrier for tumor associated carbohydrate antigens.
Yin Z; Nguyen HG; Chowdhury S; Bentley P; Bruckman MA; Miermont A; Gildersleeve JC; Wang Q; Huang X
Bioconjug Chem; 2012 Aug; 23(8):1694-703. PubMed ID: 22812480
[TBL] [Abstract][Full Text] [Related]
26. Glyco-decorated tobacco mosaic virus as a vector for cisplatin delivery.
Liu X; Liu B; Gao S; Wang Z; Tian Y; Wu M; Jiang S; Niu Z
J Mater Chem B; 2017 Mar; 5(11):2078-2085. PubMed ID: 32263681
[TBL] [Abstract][Full Text] [Related]
27. Integration of Cell-Penetrating Peptides with Rod-like Bionanoparticles: Virus-Inspired Gene-Silencing Technology.
Tian Y; Zhou M; Shi H; Gao S; Xie G; Zhu M; Wu M; Chen J; Niu Z
Nano Lett; 2018 Sep; 18(9):5453-5460. PubMed ID: 30091612
[TBL] [Abstract][Full Text] [Related]
28. Nanoparticle co-delivery of wortmannin and cisplatin synergistically enhances chemoradiotherapy and reverses platinum resistance in ovarian cancer models.
Zhang M; Hagan CT; Min Y; Foley H; Tian X; Yang F; Mi Y; Au KM; Medik Y; Roche K; Wagner K; Rodgers Z; Wang AZ
Biomaterials; 2018 Jul; 169():1-10. PubMed ID: 29631163
[TBL] [Abstract][Full Text] [Related]
29. Targeted delivery of platinum-taxane combination therapy in ovarian cancer.
Desale SS; Soni KS; Romanova S; Cohen SM; Bronich TK
J Control Release; 2015 Dec; 220(Pt B):651-9. PubMed ID: 26381902
[TBL] [Abstract][Full Text] [Related]
30. Elongated Plant Virus-Based Nanoparticles for Enhanced Delivery of Thrombolytic Therapies.
Pitek AS; Wang Y; Gulati S; Gao H; Stewart PL; Simon DI; Steinmetz NF
Mol Pharm; 2017 Nov; 14(11):3815-3823. PubMed ID: 28881141
[TBL] [Abstract][Full Text] [Related]
31. Tobacco Mosaic Virus with Peroxidase-Like Activity for Cancer Cell Detection through Colorimetric Assay.
Guo J; Zhao X; Hu J; Lin Y; Wang Q
Mol Pharm; 2018 Aug; 15(8):2946-2953. PubMed ID: 29300485
[TBL] [Abstract][Full Text] [Related]
32. Uptake-release by MSCs of a cationic platinum(II) complex active in vitro on human malignant cancer cell lines.
Rimoldi I; Coccè V; Facchetti G; Alessandri G; Brini AT; Sisto F; Parati E; Cavicchini L; Lucchini G; Petrella F; Ciusani E; Pessina A
Biomed Pharmacother; 2018 Dec; 108():111-118. PubMed ID: 30218855
[TBL] [Abstract][Full Text] [Related]
33. Speciation of Phenanthriplatin and Its Analogs in the Core of Tobacco Mosaic Virus.
Vernekar AA; Berger G; Czapar AE; Veliz FA; Wang DI; Steinmetz NF; Lippard SJ
J Am Chem Soc; 2018 Mar; 140(12):4279-4287. PubMed ID: 29553267
[TBL] [Abstract][Full Text] [Related]
34. Enhancing Cisplatin Efficacy with Low Toxicity in Solid Breast Cancer Cells Using pH-Charge-Reversal Sericin-Based Nanocarriers: Development, Characterization, and
Bahremand K; Aghaz F; Bahrami K
ACS Omega; 2024 Mar; 9(12):14017-14032. PubMed ID: 38560009
[TBL] [Abstract][Full Text] [Related]
35. Combining disulfiram and poly(l-glutamic acid)-cisplatin conjugates for combating cisplatin resistance.
Song W; Tang Z; Shen N; Yu H; Jia Y; Zhang D; Jiang J; He C; Tian H; Chen X
J Control Release; 2016 Jun; 231():94-102. PubMed ID: 26928530
[TBL] [Abstract][Full Text] [Related]
36. Effect of cisplatin-based chemotherapy on emergence of cisplatin resistance, and its correlation with intracellular glutathione levels and accumulation of p53 protein in human ovarian cancer.
Juvekar AS; Adwankar MK; Tongaonkar HB
Cancer Biother Radiopharm; 2000 Jun; 15(3):295-300. PubMed ID: 10941537
[TBL] [Abstract][Full Text] [Related]
37. Site-selective nucleation and controlled growth of gold nanostructures in tobacco mosaic virus nanotubulars.
Zhou K; Zhang J; Wang Q
Small; 2015 Jun; 11(21):2505-9. PubMed ID: 25612918
[TBL] [Abstract][Full Text] [Related]
38. Studies on the aggregation reactions and basic dye binding of tobacco mosaic virus. I. Variation of pH, particle asymmetry, acid and base titration results, irreversible binding of methylene blue, ultraviolet absorption, and extent of heat denaturation in tobacco mosaic virus solutions with time of standing.
WELSH RS
J Gen Physiol; 1956 Jan; 39(3):437-71. PubMed ID: 13286459
[TBL] [Abstract][Full Text] [Related]
39. TMV-peptide fusion vaccines induce cell-mediated immune responses and tumor protection in two murine models.
McCormick AA; Corbo TA; Wykoff-Clary S; Nguyen LV; Smith ML; Palmer KE; Pogue GP
Vaccine; 2006 Sep; 24(40-41):6414-23. PubMed ID: 16860441
[TBL] [Abstract][Full Text] [Related]
40. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.
Holloway RW; Mehta RS; Finkler NJ; Li KT; McLaren CE; Parker RJ; Fruehauf JP
Gynecol Oncol; 2002 Oct; 87(1):8-16. PubMed ID: 12468336
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
